HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

PRIMARY BILIARY CIRRHOSIS: DIAGNOSTIC CRITERIA AND THE AUTHORS’ EXPERIENCE WITH THERAPY

Download full text PDF
Issue: 
1
Year: 
2015

I. Khlynov, MD; M. Chikunova, Candidate of Medical Sciences Ural State Medical University, Yekaterinburg

The incidence rate of primary biliary cirrhosis (PBC) is 4 to 40 per 100,000 in people of different ethnicities. The basic morphological substrate of the disease is autoimmune nonpurulent destructive cholangitis characterized by the development of clinical and laboratory intrahepatic cholestasis. The treatment of PBC involves mandatory long use of ursodeoxycholic acid (UDCA) in a dose of 13–15 mg/ kg/day. The authors’ experience with UDCA in the retrospective investigation demonstrates it necessary to study the clinical efficacy of its preparations in randomized controlled prospective trials.

Keywords: 
primary biliary cirrhosis
diagnosis
treatment



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Parikh-Patel A., Gold E., Worman H. et al. Risk factors for primary biliary 1. cirrhosis in a cohort of patients from the United States // Hepatology. – 2001; 33: 16–21.
  2. Howel D., Fischbacher C., Bhopal R. et al. An exploratory population–based 2. case–control study of primary biliary cirrhosis // Hepatology. – 2000; 31: 1055–60.
  3. Sood S., Gow P., Christie J. et al. Epidemiology of primary biliary cirrhosis in 3. Victoria, Australia: high prevalence in migrant populations // Gastroenterology. – 2004; 127: 470–5.
  4. Bittencourt P., Farias A., Abrantes-Lemos C. et al. Prevalence of immune 4. disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis // J. Gastroenterol. Hepatol. – 2004; 19: 873–8
  5. Selmi C., Mayo M., Bach N. et al. Primary biliary cirrhosis in monozygotic 5. and dizygotic twins: genetics, epigenetics, and environment // Gastroenterology. – 2004; 127: 485–92.
  6. Locke G. III, Therneau T., Ludwig J. et al. Time course of histological 6. progression in primary biliary cirrhosis // Hepatology. – 1996; 23: 52–6.
  7. Corpechot C., Carrat F., Bonnand A. et al. The effect of ursodeoxycholic acid 7. therapy on liver fibrosis progression in primary biliary cirrhosis // Hepatology. – 2000; 32: 1196–9.
  8. Corpechot C., Carrat F., Bahr A. et al. The effect of ursodeoxycholic acid 8. therapy on the natural course of primary biliary cirrhosis // Gastroenterology. – 2005; 128: 297–303.
  9. Scheuer P. Primary biliary cirrhosis // Proc. R. Soc. Med. – 1967; 60: 9. 1257–60.
  10. Ivashkin V.T., Shirokova E.N., Maevskaja M.V. i dr. Klinicheskie reko-10. mendatsii po diagnostike i lecheniju holestaza. 2013; 37 s. [Elektronnyj resurs]. URL : http : // www.rsls.ru (data obraschenija: 14.12.2014)